Acelyrin, Inc.
8.80%
8,824,693
1962918
00445A100
Mar 9, 2025
Mar 12, 2025, 05:58 PM
Reporting Persons (7)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | Other | 8.80% | 8,824,693 | 0 | 8,824,693 |
| KEVIN TANG | Individual | 8.80% | 8,824,693 | 0 | 8,824,693 |
| TANG CAPITAL PARTNERS, LP | Partnership | 5.00% | 4,963,009 | 0 | 4,963,009 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 3.80% | 3,861,684 | 0 | 3,861,684 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.00% | 0 | 0 | 0 |
| CONCENTRA BIOSCIENCES, LLC | Other | 0.00% | 0 | 0 | 0 |
Disclosure Items (4)
Common Stock, par value $0.00001 per share
Acelyrin, Inc.
4149 LIBERTY CANYON RD., AGOURA HILLS, CA, 91301
Item 3 of the Original Schedule 13D is hereby amended to add the following: Since February 27, 2025 the Reporting persons have expended an aggregate of approximately $4.1 million to purchase 1,526,365 shares of the Issuer's Common Stock through the open market. The Common Stock was acquired in the ordinary course of business.
The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 8,824,693 shares of the Issuer's Common Stock, representing 8.8% of the outstanding shares.
See item 5(a) above.
Schedule A attached hereto as Exhibit 3 describes all transactions in the Issuer's Common Stock that were effected during the past 60 days by the Reporting Persons.
No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.
Not applicable
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on February 20, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 2: Acquisition Proposal, dated February 20, 2025, sent from Concentra to the Issuer (filed as Exhibit 2 of the 13D filed on February 20, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 3: Schedule A: Transactions during the past 60 days (as amended).